Animals : an open access journal from MDPI · 2025
Efficacy of a Once-Daily Supplement in Managing Canine Chronic Kidney Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perondi Francesca, Ruggiero Alessio, Cutrignelli Monica Isabella, Lippi Ilaria, Meineri Giorgia, Martello Elisa
Аннотация
BACKGROUND: Chronic kidney disease (CKD) in companion animals leads to progressive renal deterioration and metabolic complications such as hyperphosphatemia and metabolic acidosis, particularly in advanced stages.
METHODS: This 90-day, double-blind, randomized controlled study evaluated the effects of a renal supplement (Renal Combi, Candioli srl, Beinasco, Turin, Italy) in 30 dogs diagnosed with CKD. Dogs were randomly assigned to a treatment group (TRT, n = 15), receiving a commercial renal diet plus the supplement (once daily), or a control group (CTR, n = 15), receiving the same diet and a placebo.
RESULTS: Results showed that supplementation effectively reduced proteinuria, blood urea, and phosphorus levels, stabilized creatinine and SDMA, and maintained blood pressure. It also improved markers of systemic inflammation and oxidative stress.
CONCLUSIONS: The once-daily dosage simplified administration and was especially beneficial for hyporexic dogs or those on multiple medications. This study supports the use of the tested supplement as an effective adjunctive therapy for managing CKD in dogs, offering metabolic, renal, and nutritional benefits while enhancing compliance through convenient dosing.
METHODS: This 90-day, double-blind, randomized controlled study evaluated the effects of a renal supplement (Renal Combi, Candioli srl, Beinasco, Turin, Italy) in 30 dogs diagnosed with CKD. Dogs were randomly assigned to a treatment group (TRT, n = 15), receiving a commercial renal diet plus the supplement (once daily), or a control group (CTR, n = 15), receiving the same diet and a placebo.
RESULTS: Results showed that supplementation effectively reduced proteinuria, blood urea, and phosphorus levels, stabilized creatinine and SDMA, and maintained blood pressure. It also improved markers of systemic inflammation and oxidative stress.
CONCLUSIONS: The once-daily dosage simplified administration and was especially beneficial for hyporexic dogs or those on multiple medications. This study supports the use of the tested supplement as an effective adjunctive therapy for managing CKD in dogs, offering metabolic, renal, and nutritional benefits while enhancing compliance through convenient dosing.